Psilocybin Therapy for Depression: A Latest Hope?

For individuals grappling with depression, conventional treatments like medication and psychotherapy aren’t always sufficient. Approximately 30% of those affected find existing medications ineffective and up to 80% experience relapse within a year. Now, a growing body of research is exploring psilocybin – a naturally occurring compound found in “magic mushrooms” – as a potential new avenue for treatment. Recent studies, particularly those conducted in Germany, are examining the opportunities and limitations of this approach.

The German Study: Examining Psilocybin’s Effects

A study published in JAMA Psychiatry followed 144 people with chronic depression, many of whom had previously tried and failed to find relief from five or more antidepressants. [3] Participants were divided into three groups to assess the impact of different psilocybin dosages:

• 25 milligrams of psilocybin: The “full dose” commonly used in research.
• 5 milligrams of psilocybin: A lower dose designed to produce less intense effects.
• Nicotinamide: A placebo intended to mimic some of the physical sensations associated with psilocybin.

The treatment involved two sessions, spaced six weeks apart. Each session was carefully supervised by experienced therapists, recognizing that psilocybin can induce significant alterations in perception and emotions. Intensive preparation and follow-up care were integral components of the treatment protocol.

Modest Improvements, Not a Cure

While psilocybin therapy, combined with psychotherapy, demonstrated some positive effects after six weeks, the study did not achieve its primary goal of halving depression symptoms. Professor Gerhard Gründer, the study leader, noted that the more modest results in a larger patient group were consistent with the trend observed when moving from smaller, preliminary studies. [1]

Though, the 25-milligram dose did result in measurable and clinically relevant symptom relief, on average. Interestingly, a second full dose did not provide any additional benefit. Individual responses varied considerably, ranging from minimal improvement to substantial positive change. One patient reportedly told their psychiatrist of 20 years, “I’m not coming anymore, I’m cured.”

How Does Psilocybin Work?

Research suggests psilocybin promotes the formation of new nerve growth hormones and synapses, essentially allowing brain regions to reconnect. [1] These changes can facilitate deep insights and emotional breakthroughs, potentially leading to remission of depressive symptoms.

Risks and Side Effects

The study underscored the importance of careful monitoring during psilocybin treatment. The substance is not without risks. Side effects, particularly at the 25-milligram dose, ranged from temporary discomfort to more serious complications.

• Psychological Stress: Many participants experienced intense emotional reactions during sessions, which could be frightening or distressing.
• Physical Complaints: Headaches, nausea, and elevated blood pressure were common, though typically short-lived.
• Serious Side Effects: Increased suicidal thoughts were reported by some participants on treatment days, highlighting the need for close therapeutic support. One patient experienced panic attacks requiring hospitalization, and another presented with an acute blood pressure crisis requiring emergency care.

Experts strongly caution against the unsupervised apply of psilocybin. Dr. Matthias Jungwirth of the Charité in Berlin emphasizes that psilocybin should only be administered within a therapeutic context. [2]

Germany’s Compassionate Use Program

In July 2025, Germany became the first country in the European Union to launch a compassionate use program for psilocybin, allowing certain patients with treatment-resistant depression to access the therapy under strictly controlled conditions. [1] The Central Institute of Mental Health (CIMH) in Mannheim received approval to offer psilocybin to individual patients in Mannheim and Berlin in justified exceptional cases. [2] This program is not a substitute for full regulatory approval, which is still several years away.

Future Outlook

Independent experts have praised the study’s rigorous methodology. While further research is needed to identify which patient groups would benefit most and to refine treatment protocols, psilocybin remains a promising therapeutic avenue. Professor Gründer anticipates potential approval in the United States within one to two years, though European approval is expected to capture considerably longer. Demand for this treatment is already substantial.

Where to Find Help

If you are experiencing depression, please reach out for help:

• Nationwide Telephone Counseling Service: Provides support and guidance.
• German Depression Relief Foundation: Offers support via email, chat, and telephone.
• In Acute Crisis: Contact a psychiatric clinic or call 112 for emergency assistance.
• Consult a Doctor or Psychotherapist: Your family doctor or online platforms can help with finding a qualified professional.